MADCAP: Precision Interception of Aggressive Prostate Cancer in African American Men

Funded by NIH/NCI, Grant # 1P20CA233255-01

Prostatic adenocarcinoma (PCa) is the most frequently diagnosed non-cutaneous malignancy and a leading cause of male cancer death. African American (AA) men die from PCa at a rate more than double that of men of any other race or ethnicity. The causes of this disparity are multifactorial and certainly include unequal access to screening and treatment. Biological differences in the tumors of AA and non-AA men have also been reported that may reflect underlying tumor differences that may also affect prognosis and treatment choice. Our ability to predict and monitor PCa progression and make better treatment choices in AA men is critical to reducing disparities in PCa among AA men.

To address these issues, we propose a “precision interception” approach designed to impede cancer progression at early stages and avoid development of lethal disease in AA PCa cases. Precision interception approaches use knowledge of molecular signatures and other clinical and epidemiological data to interrupt PCa before it is lethal to the patient. Thus, our proposal will focus on newly diagnosed or recurrent AA PCa patients, with the goal to develop and implement tools that can “intercept” the development of castrate-resistant or metastatic PCa and death from PCa in AA men. These approaches can thereby reduce PCa-specific disparities in mortality experienced by AA men.

We will use the “Men of African Descent and Carcinoma of the Prostate” (MADCaP) network that has substantial resources to address disparities in PCa in AA men. The team assembled here has previously collaborated to develop translational research that is led by established basic and clinical experts who have worked together to develop each concept. The result is a novel inter-disciplinary collaboration with the potential to maximize clinical impact on PCa disparities in AA men. Our proposed translational research should have substantial translational/clinical impact, improve management of and outcomes, and reduce PCa disparities in AA men with PCa.

The SPORE features three projects which address critical problems in this area, which are supported by two cores, a developmental research program and a career enhancement program.

If you are interested in becoming involved in this SPORE, please contact: 

Timothy Rebbeck, PhD

Vincent L. Gregory, Jr. Professor of Cancer Prevention,
Harvard TH Chan School of Public Health
Division of Population Sciences, Dana-Farber Cancer Institute.
450 Brookline Avenue, 1101 Dana Building, Boston, MA 02215
Telephone: 617-632-6128

SPORE Administration

Tina Dasilva

Director, Grants and Contracts

Leah Gibbons

Manager, Department Grants Management

Michelle Lee-Bravatti

Research Project Manager